中国P站

Extracellular Vesicles; Liquid Biopsy; Biomarkers; Artificial Intelligence; MicroRNAs; Proteomics; Genomics; Telomeres; Cell-free DNA; Early Cancer Detection

Introduction

Extracellular Vesicles (EVs) show promise as diagnostic markers in cancer[1].

Detecting specific EV cargos like microRNAs and proteins allows for non-invasive early detection and monitoring of treatment response[1].

Liquid biopsies are gaining traction as a minimally invasive approach for early cancer detection[2].

Analyzing circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) provides valuable information about tumor genetics and stage[2].

The combination of multiple biomarkers improves the sensitivity and specificity of early cancer detection[3].

Integrating genomic, proteomic, and metabolomic data enhances the accuracy of diagnostic tests[3].

Artificial Intelligence (AI) and Machine Learning (ML) are being applied to analyze complex biomarker data and improve the accuracy of cancer diagnosis[4].

AI-powered tools can identify subtle patterns that may be missed by human observers[4].

Glycans and glycan-related molecules are emerging as promising biomarkers for cancer diagnosis[5].

Aberrant glycosylation patterns can differentiate between cancerous and normal cells, facilitating early detection[5].

MicroRNAs (miRNAs) offer a stable and detectable source of biomarkers for early cancer diagnosis[6].

Specific miRNA signatures can distinguish between different cancer types and stages[6].

Volatile organic compounds (VOCs) in breath samples are showing potential for non-invasive cancer screening[7].

Specific VOC profiles can distinguish between healthy individuals and those with cancer[7].

Proteomic analysis of serum and plasma samples enables the identification of novel protein biomarkers for early cancer detection[8].

Mass spectrometry-based techniques are used to quantify protein abundance and identify cancer-specific protein signatures[8].

Telomere length and telomerase activity are being explored as potential biomarkers for cancer diagnosis[9].

Alterations in telomere maintenance mechanisms are associated with cancer development and progression[9].

Circulating cell-free DNA (cfDNA) methylation patterns show promise as a non-invasive marker for early cancer detection[10].

Epigenetic alterations in cfDNA can distinguish between healthy individuals and those with cancer[10].

Description

Extracellular Vesicles (EVs) are at the forefront of cancer diagnostics, offering a non-invasive route to early detection[1]. Their ability to transport specific cargos, like microRNAs and proteins, allows for real-time monitoring of treatment response, marking a significant step forward in personalized medicine[1]. The focus on EVs underscores a shift towards less invasive, more precise diagnostic methods, potentially revolutionizing how we approach cancer care.

Liquid biopsies are rapidly becoming a preferred method for early cancer detection, offering a minimally invasive alternative to traditional biopsies[2]. By analyzing circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs), clinicians gain valuable insights into the tumor's genetic makeup and stage, facilitating more informed treatment decisions[2]. The accessibility of liquid biopsies enhances patient comfort and allows for frequent monitoring, enabling timely adjustments to treatment plans. This approach, when combined with multiple biomarkers, improves sensitivity and specificity in early cancer detection[3].

Artificial Intelligence (AI) and Machine Learning (ML) are transforming the landscape of cancer diagnosis, providing tools to analyze complex biomarker data with unprecedented accuracy[4]. These technologies can identify subtle patterns that might be missed by human observers, leading to earlier and more accurate diagnoses[4]. Glycans and glycan-related molecules are also being investigated for their potential as cancer biomarkers[5]. Aberrant glycosylation patterns can distinguish between cancerous and normal cells, offering another avenue for early detection[5].

MicroRNAs (miRNAs) represent another promising class of biomarkers, offering a stable and detectable source for early cancer diagnosis[6]. Specific miRNA signatures can differentiate between various cancer types and stages, enabling clinicians to tailor treatment strategies[6]. Additionally, volatile organic compounds (VOCs) in breath samples are being explored as a non-invasive screening tool[7]. Distinct VOC profiles can distinguish between healthy individuals and those with cancer, providing a convenient and accessible method for early detection[7]. Proteomic analysis of serum and plasma samples is also enabling the identification of novel protein biomarkers[8]. Mass spectrometry-based techniques are used to quantify protein abundance and identify cancer-specific protein signatures[8]. Finally, telomere length and telomerase activity are being investigated as potential biomarkers, with alterations in telomere maintenance mechanisms linked to cancer development[9] and circulating cell-free DNA (cfDNA) methylation patterns showing promise[10].

Conclusion

Early cancer detection is significantly advancing through the exploration of various biomarkers and technologies. Extracellular Vesicles (EVs) are emerging as promising diagnostic markers, enabling non-invasive early detection and treatment monitoring by analyzing specific EV cargos like microRNAs and proteins. Liquid biopsies offer a minimally invasive approach, analyzing circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) to provide valuable insights into tumor genetics and stage. The integration of multiple biomarkers, including genomic, proteomic, and metabolomic data, enhances the accuracy of diagnostic tests. Artificial Intelligence (AI) and Machine Learning (ML) are being utilized to analyze complex biomarker data, improving the accuracy of cancer diagnosis by identifying subtle patterns. Glycans and glycan-related molecules are also showing promise, with aberrant glycosylation patterns differentiating between cancerous and normal cells. MicroRNAs (miRNAs) serve as stable and detectable biomarkers, with specific miRNA signatures distinguishing between different cancer types and stages. Volatile Organic Compounds (VOCs) in breath samples offer a non-invasive screening method, where specific VOC profiles can differentiate between healthy individuals and those with cancer. Proteomic analysis of serum and plasma samples identifies novel protein biomarkers, using mass spectrometry-based techniques to quantify protein abundance. Telomere length and telomerase activity are being explored, with alterations in telomere maintenance mechanisms associated with cancer development. Finally, circulating cell-free DNA (cfDNA) methylation patterns are emerging as a non-invasive marker, with epigenetic alterations in cfDNA distinguishing between healthy individuals and those with cancer.

References

1. Theresa W, Manuela J, Sven B (2023) .Chem Soc Rev 52:5596-5650.

   , ,

2. Ignacio B, Ana V, Luis S (2022) .Cancers (Basel) 14:2786.

   , ,

3. Timo H, Juha K, Olli K (2021) .Breast Cancer Res 23:43.

   , ,

4. Zhe X, Wei D, Song Y (2020) .J Cancer Res Clin Oncol 146:2199-2213.

   , ,

5. Ahmed EY, Ahmed OA, Amr SS (2019) .Future Oncol 15:3273-3287.

   , ,

6. Shuying S, Xiaojie Z, Yan Z (2024) .Mol Cancer 23:101.

   , ,

7. Daniele P, Federica V, Giuseppina MM (2023) .J Breath Res 17:014001.

   , ,

8. Karin RR, Anna L, Karin V (2022) .Biochim Biophys Acta Proteins Proteom 1870:140319.

   , ,

9. Maria AC, Carla O, Mariana V (2021) .Cancers (Basel) 13:1765.

   , ,

10. Daniel DC, Stefanie C, Matthias S (2020) .Cancers (Basel) 12:1639.

    , ,